AMINOPLASMAL 100g/l România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

aminoplasmal 100g/l

b. braun melsungen ag - combinatii - sol. perf. - 100g/l - solutii pentru administrare intravenoasa solutii pentru nutritie parenterala

AMINOPLASMAL 100 g/l CU ELECTROLITI România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

aminoplasmal 100 g/l cu electroliti

b. braun melsungen ag - germania - combinatii - sol. perf. - 100mg/ml - solutii pentru administrare intravenoasa solutii pentru alimentatie parenterala

AMINOPLASMAL 100g/l E România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

aminoplasmal 100g/l e

b. braun melsungen ag - combinatii - sol. perf. - 100g/l - solutii pentru administrare intravenoasa solutii pentru nutritie parenterala

AMINOPLASMAL 50g/l E România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

aminoplasmal 50g/l e

b. braun melsungen ag - combinatii - sol. perf. - 50g/l - solutii pentru administrare intravenoasa solutii pentru nutritie parenterala

AMINOPLASMAL HEPA 100 g/l România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

aminoplasmal hepa 100 g/l

b. braun melsungen ag - germania - combinatii - sol. perf. - 100g/l - solutii pentru administrare intravenoasa solutii pentru nutritie parenterala

Mhyosphere PCV ID Uniunea Europeană - română - EMA (European Medicines Agency)

mhyosphere pcv id

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - porci - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

OCTAPLASLG 45-70 mg/ml România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

octaplaslg 45-70 mg/ml

octapharma ab - suedia - proteine plasmatice umane de grup sanguin a,b,, 0 - sol. perf. - 45-70mg/ml - sange si substituenti de sange substituenti de sange si fractiuni proteice plasmatice